Latest headcount
17
YoY change
0.0%
Headcount CAGR
+19.5%
Revenue / employee
$2.6K
Employee count history for Relmada Therapeutics
| Fiscal year | Employees |
|---|---|
| 2013 | 2 |
| 2015 | 11 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 14 |
| 2021 | 10 |
| 2022 | 14 |
| 2023 | 20 |
| 2024 | 17 |
| 2025 | 17 |
Earnings per employee for Relmada Therapeutics
Annual net income divided by reported headcount, normalized to US dollars; years with a net loss dip below zero.
| Fiscal year | Earnings per employee (USD) |
|---|---|
| 2013 | -$22.5K |
| 2015 | -$1.9M |
| 2016 | -$495.8K |
| 2017 | -$2.1M |
| 2018 | -$3M |
| 2019 | -$4.3M |
| 2020 | -$4.2M |
| 2021 | -$12.6M |
| 2022 | -$11.2M |
| 2023 | -$4.9M |
| 2024 | -$4.7M |
| 2025 | -$3.4M |
Employee count history for Relmada Therapeutics (RLMD)
Annual figures come from annual reports (10-K, or 20-F/40-F for foreign filers); interim rows reflect headcount disclosed in periodic filings. Year-over-year change compares each filing with the prior year's equivalent. Revenue and earnings per employee are annual figures normalized to US dollars.
- 2025170.0%
- 202417-15.0%
- 202320+42.9%
- 202214+40.0%
- 202110-28.6%
- 202014+250.0%
- 20194+33.3%
- 201830.0%
- 20173-50.0%
- 20166-45.5%
- 201511—
- 20132—
About Relmada Therapeutics's employee count
Relmada Therapeutics (RLMD) employed 17 people in fiscal year 2025, based on its most recent annual report. That headcount was unchanged from 17 a year earlier.
Across the 2013–2025 period, the company's reported workforce went from 2 to 17 employees — a compound annual growth rate (CAGR) of +19.5% per year.
Relmada Therapeutics generated about $2.6K of revenue and -$3.4M of net income per employee in its latest annual period. Revenue and earnings per employee gauge how efficiently a company turns headcount into output, and are most telling when tracked over time or compared with peers in the same industry.
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation